-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
MiNK Therapeutics (NASDAQ:INKT) Versus Voyager Therapeutics (NASDAQ:VYGR) Head to Head Comparison
MiNK Therapeutics (NASDAQ:INKT) Versus Voyager Therapeutics (NASDAQ:VYGR) Head to Head Comparison
Voyager Therapeutics (NASDAQ:VYGR – Get Rating) and MiNK Therapeutics (NASDAQ:INKT – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.
Earnings and Valuation
This table compares Voyager Therapeutics and MiNK Therapeutics' top-line revenue, earnings per share and valuation.
Get Voyager Therapeutics alerts:| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Voyager Therapeutics | $37.42 million | 6.45 | -$71.20 million | ($0.46) | -13.59 |
| MiNK Therapeutics | $690,000.00 | 112.62 | -$30.21 million | ($0.78) | -2.95 |
MiNK Therapeutics has lower revenue, but higher earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
59.4% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 1.1% of MiNK Therapeutics shares are held by institutional investors. 22.0% of Voyager Therapeutics shares are held by insiders. Comparatively, 13.2% of MiNK Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.Volatility & Risk
Voyager Therapeutics has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of -0.63, indicating that its stock price is 163% less volatile than the S&P 500.
Profitability
This table compares Voyager Therapeutics and MiNK Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Voyager Therapeutics | -24.21% | -21.97% | -8.65% |
| MiNK Therapeutics | N/A | -168.94% | -78.30% |
Analyst Recommendations
This is a breakdown of recent recommendations for Voyager Therapeutics and MiNK Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Voyager Therapeutics | 0 | 0 | 0 | 0 | N/A |
| MiNK Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
Voyager Therapeutics currently has a consensus target price of $6.00, indicating a potential downside of 4.00%. MiNK Therapeutics has a consensus target price of $7.00, indicating a potential upside of 204.35%. Given MiNK Therapeutics' higher possible upside, analysts plainly believe MiNK Therapeutics is more favorable than Voyager Therapeutics.
Summary
Voyager Therapeutics beats MiNK Therapeutics on 7 of the 13 factors compared between the two stocks.
About Voyager Therapeutics
(Get Rating)
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
About MiNK Therapeutics
(Get Rating)
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Voyager Therapeutics (NASDAQ:VYGR – Get Rating) and MiNK Therapeutics (NASDAQ:INKT – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.
旅行者治療公司(納斯達克：VYGR-GET評級)和水貂治療公司(納斯達克：iNKT-GET評級)都是小盤醫療公司，但哪隻股票更好？我們將根據兩家公司的估值、收益、股息、風險、盈利能力、分析師推薦和機構持股情況對它們進行比較。
Earnings and Valuation
收益和估值
This table compares Voyager Therapeutics and MiNK Therapeutics' top-line revenue, earnings per share and valuation.
此表比較了Voyager治療公司和水貂治療公司的營收、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Voyager Therapeutics | $37.42 million | 6.45 | -$71.20 million | ($0.46) | -13.59 |
| MiNK Therapeutics | $690,000.00 | 112.62 | -$30.21 million | ($0.78) | -2.95 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 旅行者治療公司 | 3,742萬美元 | 6.45 | -7,120萬美元 | ($0.46) | -13.59 |
| 水貂治療公司 | $690,000.00 | 112.62 | -3021萬美元 | ($0.78) | -2.95 |
MiNK Therapeutics has lower revenue, but higher earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks.
水貂治療公司的收入低於旅行者治療公司，但收益高於旅行者治療公司。Voyager治療公司的市盈率低於水貂治療公司，這表明它目前是兩隻股票中更負擔得起的一隻。
Institutional & Insider Ownership
機構與內部人持股
Volatility & Risk
波動性與風險
Voyager Therapeutics has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of -0.63, indicating that its stock price is 163% less volatile than the S&P 500.
Voyager Treateutics的貝塔係數為0.96，表明其股價的波動性比標準普爾500指數低4%。相比之下，水貂治療公司的貝塔係數為-0.63，這表明其股價的波動性比標準普爾500指數低163%。
Profitability
盈利能力
This table compares Voyager Therapeutics and MiNK Therapeutics' net margins, return on equity and return on assets.
此表比較了Voyager治療公司和水貂治療公司的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Voyager Therapeutics | -24.21% | -21.97% | -8.65% |
| MiNK Therapeutics | N/A | -168.94% | -78.30% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 旅行者治療公司 | -24.21% | -21.97% | -8.65% |
| 水貂治療公司 | 不適用 | -168.94% | -78.30% |
Analyst Recommendations
分析師建議
This is a breakdown of recent recommendations for Voyager Therapeutics and MiNK Therapeutics, as reported by MarketBeat.com.
據MarketBeat.com報道，這是Voyager治療公司和水貂治療公司最近推薦的細目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Voyager Therapeutics | 0 | 0 | 0 | 0 | N/A |
| MiNK Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 旅行者治療公司 | 0 | 0 | 0 | 0 | 不適用 |
| 水貂治療公司 | 0 | 0 | 2 | 0 | 3.00 |
Voyager Therapeutics currently has a consensus target price of $6.00, indicating a potential downside of 4.00%. MiNK Therapeutics has a consensus target price of $7.00, indicating a potential upside of 204.35%. Given MiNK Therapeutics' higher possible upside, analysts plainly believe MiNK Therapeutics is more favorable than Voyager Therapeutics.
Voyager治療公司目前的共識目標價為6.00美元，這表明潛在的下行幅度為4.00%。水貂治療公司的共識目標價為7美元，表明潛在上漲204.35%。考慮到水貂治療公司更有可能的上行空間，分析師們顯然認為水貂治療公司比旅行者治療公司更有利。
Summary
摘要
Voyager Therapeutics beats MiNK Therapeutics on 7 of the 13 factors compared between the two stocks.
Voyager治療公司在兩隻股票之間的13個因素中有7個擊敗了水貂治療公司。
About Voyager Therapeutics
關於旅行者治療公司
(Get Rating)
(獲取評級)
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Voyager治療公司是一家基因治療公司，專注於治療和下一代平臺技術的開發。該公司的主要臨牀候選藥物是VY-AADC，它正在進行治療帕金森病的開放標籤第一階段臨牀試驗。它的臨牀前計劃包括用於治療肌萎縮側索硬化症的VY-SOD102；用於亨廷頓病的VY-HTT01；用於Friedreich共濟失調的VY-FXN01；以及用於治療包括阿爾茨海默病、進行性核上性癱瘓和額顳部痴呆以及脊髓性肌萎縮症在內的各種疾病的Tau計劃。該公司與輝瑞的Neurocrine生物科學公司和A.G.諾華製藥公司就腺相關病毒基因治療產品的研究、開發和商業化達成合作和許可協議。Voyager治療公司成立於2013年，總部設在馬薩諸塞州劍橋市。
About MiNK Therapeutics
關於水貂治療公司
(Get Rating)
(獲取評級)
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
明克治療公司是一家臨牀階段的生物製藥公司，致力於同種異體、現成、不變的自然殺傷T(INKT)細胞療法的發現、開發和商業化，以治療癌症和其他免疫介導性疾病。它的候選產品是AGENT-797，這是一種現成的同種異體藥物，用於iNKT細胞治療和治療各種骨髓瘤疾病，目前處於第一階段臨牀試驗。該公司前身為AgenTus治療公司。水貂治療公司成立於2017年，總部設在紐約。明克治療公司是Agenus公司的子公司。
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受旅行者治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收Voyager Treeutics和相關公司的最新新聞和分析師評級的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧